CLINICAL TRIALS PROFILE FOR NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

All Clinical Trials for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	US Department of Veterans Affairs		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	VA Office of Research and Development		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00093925 ↗	Clevidipine in the Postoperative Treatment of Hypertension (ECLIPSE-NIC)	Completed	The Medicines Company	Phase 3	2004-05-01	The purpose of this study is to establish the safety of clevidipine in the treatment of postoperative hypertension. Approximately 250-500 patients with postoperative hypertension after undergoing coronary artery bypass grafting (CABG), off-pump coronary artery bypass (OPCAB) or minimally invasive direct coronary artery bypass (MIDCAB) surgery and/or valve replacement/repair procedures were anticipated to be randomly assigned to one of two treatment groups: clevidipine or nicardipine.
NCT00137501 ↗	Two Dose Regimens of Nifedipine for the Management of Preterm Labor	Terminated	American University of Beirut Medical Center	Phase 3	2003-05-01	Preterm birth is one of the most important causes of perinatal morbidity and mortality worldwide. Prevention and treatment of preterm labor is important, not as an end in itself, but as a means of reducing adverse events for the neonate. A wide range of tocolytics, drugs used to suppress uterine contractions, have been tried. Magnesium sulfate (MgSO4) is the most widely used tocolytic at the American University of Beirut Medical Center despite the fact that an effective tocolytic role of MgSO4 has never been established. Moreover, the currently available data are suggestive of deleterious fetal effects of MgSO4 in the setting of preterm labor to the extent that some authorities are recommending abandoning it for routine use as a tocolytic therapy. Calcium channel blockers have the ability to inhibit contractility in smooth muscle cells. Consequently, nifedipine has emerged as an effective and rather safe alternative tocolytic agent for the management of preterm labor after several studies have shown that the use of nifedipine in comparison with other tocolytics is associated with a more frequent successful prolongation of pregnancy, resulting in significantly fewer admissions of newborns to the neonatal intensive care unit, and is associated with a lower incidence of respiratory distress syndrome. The unequivocal impact of this method of tocolysis on short term postponement of delivery and the opportunity that this provides for affecting in-utero transfer and steroid administration has prompted many investigators to recommend focusing future trials on testing different dose regimens of nifedipine. To the best of the investigators' knowledge, no study comparing two different dose regimens of nifedipine has been previously published in the literature. The objective of their study is to compare the effectiveness of a high versus a low dose regimen in a total of 200 patients admitted with the diagnosis of preterm labor between 24 and 34 weeks of gestation. In addition, the investigators' study will try to assess the safety profile of the 2 dose regimens on the mother and the neonate by assessing a selected number of outcome variables. The data generated will be used to change their protocol for managing patients presenting with threatened preterm delivery and will fill the existing gap regarding the most effective and safest dose regimen of nifedipine in such patients.
NCT00226096 ↗	Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage	Completed	National Health and Medical Research Council, Australia	N/A	2005-11-01	The purpose of the study is to determine whether lowering high blood pressure levels after the start of a stroke caused by bleeding in the brain (intracerebral haemorrhage) will reduce the chances of a person dying or surviving with a long term disability. The study will be undertaken in two phases: a vanguard phase in 400 patients, to plan for a main phase in 2000 patients.

Clinical Trial Conditions for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

Condition Name

Condition Name for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
Intervention	Trials
Hypertension	10
Subarachnoid Hemorrhage	4
Intracerebral Hemorrhage	3
Coronary Artery Disease	2

Condition MeSH

Condition MeSH for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
Intervention	Trials
Hypertension	13
Hemorrhage	9
Cerebral Hemorrhage	6
Subarachnoid Hemorrhage	6

Clinical Trial Locations for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

Trials by Country

Trials by Country for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
Location	Trials
United States	93
China	31
Japan	5
Australia	5
Korea, Republic of	5

Trials by US State

Trials by US State for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
Location	Trials
Illinois	7
New York	6
Ohio	6
Pennsylvania	5
North Carolina	4

Clinical Trial Progress for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

Clinical Trial Phase

Clinical Trial Phase for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
Clinical Trial Phase	Trials
PHASE4	3
Phase 4	14
Phase 3	11

Clinical Trial Status

Clinical Trial Status for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
Clinical Trial Phase	Trials
Completed	24
Not yet recruiting	10
RECRUITING	9

Clinical Trial Sponsors for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

Sponsor Name

Sponsor Name for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
Sponsor	Trials
The Medicines Company	4
Yonsei University	4
National Institute of Neurological Disorders and Stroke (NINDS)	3

Sponsor Type

Sponsor Type for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
Sponsor	Trials
Other	154
Industry	12
NIH	3

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE Market Analysis and Financial Projection

Last updated: April 25, 2026

Nicardipine Hydrochloride in 0.9% Sodium Chloride: Clinical Trials, Market Read-Across, and Projection

What is the product scope?

Nicardipine hydrochloride in 0.9% sodium chloride is an IV formulation used to manage hypertensive emergencies and related blood-pressure control settings where titratable IV therapy is required. The clinical-development and commercial landscape is dominated by:

• Nicardipine IV (solution) brands and authorized generics (brand-to-generic substitution in hospital channels).
• Labeling alignment around hypertensive emergencies, perioperative blood-pressure control, and off-label uses in ICU settings.
• Formulation comparability (concentration, container system, infusion compatibility, and stability in sodium chloride).

This update focuses on the drug substance nicardipine delivered as an IV hydrochloride salt in 0.9% sodium chloride as the marketed dosage form that drives prescribing and procurement decisions.

---

What is the clinical trials signal in this formulation category?

Public clinical-trial activity for nicardipine itself is mature, with most current “signal” in practice coming from:

• Comparative blood-pressure control studies (nicardipine vs. alternative IV antihypertensives such as clevidipine, nitroglycerin, labetalol, or sodium nitroprusside, depending on indication)
• Perioperative studies (neurosurgery, cardiac surgery, and ICU protocols)
• Formulation-performance evidence (stability, infusion compatibility, and practical administration rather than new pharmacology)

For the specific combination “nicardipine hydrochloride in 0.9% sodium chloride,” the development pipeline is generally not characterized by late-stage, molecule-defining trials because nicardipine is already established and the IV formulation is typically handled as a reformulation/comparability exercise rather than a new clinical entity.

Clinical update implication for investors/R&D:

• New entrants typically compete on access, supply reliability, and cost rather than differentiation by new clinical endpoints.
• Any pipeline value is concentrated in regulatory strategy (ANDA/bridging packages, labeling expansions where feasible) and operational execution.

---

What does the market structure look like?

The market for IV nicardipine is typically accessed via:

• Hospital formularies (ICU, stroke/neurocritical care, perioperative anesthesia)
• Acute hypertensive emergency protocols
• Pharmacy procurement with substitution across brands and generics

Key demand drivers:

• High-volume ICU utilization and standardized BP-control pathways.
• Preference for agents with rapid titration and predictable onset.
• Formularies favoring drugs with stable supply and pricing.

Competitive landscape attributes:

• Generics tend to compress margin and increase buying behavior around acquisition cost.
• Brand differentiation is mostly historical; present differentiation usually comes from availability and packaging constraints rather than clinical superiority.

---

Where does nicardipine stack up versus alternatives?

In acute BP control, formularies commonly compare nicardipine with:

• Clevidipine
• Labetalol
• Nitroprusside
• Nitroglycerin (more vasodilatory use cases)
• Other calcium-channel blocker IV options depending on region and tendering

Decision factors in hospitals:

• Titration control and ease of administration
• Monitoring intensity and adverse-effect profile
• Supply and acquisition cost
• Local protocol fit (neurology vs cardiac vs general ICU)

Projection implication: Nicardipine’s share depends on whether hospitals standardize BP protocols around it versus clevidipine and whether generic supply remains stable and price-competitive.

---

What regulatory and IP reality drives the projection?

For an established IV drug:

• IP value typically rests on formulation-specific patents (if any) and any process or packaging protections.
• When those lapse, market access shifts toward generic entry and tender-driven procurement.

Projection implication:

• Revenue growth, if any, is mainly volume-led (hospital utilization growth) or price stabilization after initial entry.
• Margin profile generally declines post generic substitution.
• Higher-performing sellers win through contracting terms, reliability, and pharmacovigilance operations rather than new clinical value.

---

Market projection: how demand and pricing are expected to move

Because the drug is already used clinically at scale and the product is a standard IV antihypertensive formulation, the projection should be modeled around three levers:

1) Unit volume

• Stable to mildly growing with ICU admissions and hypertensive emergency prevalence patterns.
• Growth is also influenced by practice protocols (how often nicardipine is picked versus alternatives).

2) Net price (declining with generic entry)

• Expect downward price pressure after sustained generic penetration.
• Any price floor occurs through procurement contracts and scarcity episodes, if supply constraints emerge.

3) Share-of-protocol

• If local pathways shift toward competitors (notably clevidipine in certain geographies), nicardipine share can stagnate.
• If protocols emphasize calcium-channel blockade and titratability without the specific competitor’s advantages, nicardipine can hold share.

Practical projection shape:

• Short term (next 1 to 3 years): flat-to-moderate volume, price pressure persists, net revenue stable to down depending on tender effects.
• Medium term (3 to 7 years): volume growth from hospital demand offsets some price erosion, but net growth remains limited unless new labeling expands use.
• Longer term (7+ years): market behaves like a mature generic/near-generic segment unless a new differentiated formulation is introduced.

---

Revenue drivers and risks by stakeholder

For an innovator/brand owner (if still active)

• Revenue depends on contract retention and conversion rates in formularies already using nicardipine IV.
• The key risk is formulary substitution to other IV agents and generic share gains by lower-priced suppliers.

For a generic entrant

• Winning margin is procurement- and reliability-led.
• The key execution risk is supply disruption (manufacturing, regulatory maintenance, container stability).

For an investor evaluating pipeline value

• Molecule innovation is limited given nicardipine’s established clinical position.
• Pipeline value is more likely in regulatory strategy (label updates, bridging packages) and operational scaling (cost-of-goods and distribution capability).

---

Actionable takeaways for R&D and business development

What to prioritize for competitive positioning?

1. Cost and supply reliability
   • Low-cost manufacturing and consistent distribution determine tender wins.
2. Protocol fit and hospital adoption
   • Align product availability with ICU protocol preferences in target geographies.
3. Stability, infusion compatibility, and packaging performance
   • These drive pharmacy acceptance in IV admixture workflows.

What to watch in clinical trial activity?

• Comparative trials that influence protocol guidelines (especially in neurocritical and perioperative care).
• Trials that change institutional BP-control algorithms even without new drug approvals.

What is the most likely market outcome?

• The market for nicardipine IV in 0.9% sodium chloride behaves as a mature hospital IV product class with persistent generic price pressure.
• Growth is limited by substitution risk and determined primarily by contracting and utilization, not by breakthrough clinical performance.

---

Key Takeaways

• Nicardipine hydrochloride in 0.9% sodium chloride is an established IV antihypertensive used for acute blood-pressure control in hospital settings.
• Clinical-trial activity is likely to be comparative and protocol-driven rather than molecule-defining, since the core pharmacology is mature.
• Market dynamics are dominated by hospital formularies, procurement contracting, and generic price pressure, with volume gains offsetting some price erosion.
• Competitive advantage is typically operational: supply reliability, acquisition cost, and pharmacy workflow compatibility.

---

FAQs

1) Is this product likely to have active late-stage clinical development?

Late-stage molecule-defining trials are generally unlikely because nicardipine is established. Activity usually concentrates on comparative use and formulation/practical administration evidence.

2) What determines hospital adoption for nicardipine IV?

Formulary inclusion, protocol alignment, titratability, ease of administration, adverse-effect handling, and procurement pricing.

3) How does generic entry affect pricing?

Generic penetration usually drives net price down quickly and shifts value toward volume secured through tenders.

4) Which clinical settings are most relevant?

ICU hypertensive emergency protocols and perioperative care where rapid titration is required, especially in neurocritical workflows.

5) What is the biggest market risk?

Protocol substitution to alternative IV antihypertensives combined with sustained price compression from multiple generic suppliers.

---

References

1. Food and Drug Administration. Labeling and drug approval information for nicardipine hydrochloride (IV). FDA Drugs@FDA database.
2. European Medicines Agency. Assessment history and product information for nicardipine. EMA human medicines resources.
3. National Library of Medicine. ClinicalTrials.gov search results for nicardipine and IV antihypertensive comparative studies. ClinicalTrials.gov.